Jan 19, 2021

Featuring an interview with Dr Shannon N Westin on the following topics:

• Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00)
• Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46)
• Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51)
• Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56)
• Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15)
• Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03)
• Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32)
• Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19)
• Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09)
• Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14)
• Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53)

CME information and select publications